By Professor Michael Leonard Friedlander

Journal articles

Bowtell DDL; Friedlander M; Quinn M; Mitchell G, 2011, 'A response to the forgotten fallopian tube', Nature Reviews Cancer, 11, http://dx.doi.org/10.1038/nrc2946-c2

Regan MM; Price KN; Giobbie-Hurder A; Thuerlimann B; Gelber RD, 2011, 'Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer', BREAST CANCER RESEARCH, 13, http://dx.doi.org/10.1186/bcr2837

Lee CK; Hudson M; Coates A; Ackland S; Gebski V; Lord S; Friedlander M; Boyle F; Simes RJ, 2011, 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129, pp. 467 - 476, http://dx.doi.org/10.1007/s10549-011-1471-9

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2011, 'A specialist breast care nurse role for women with metastatic breast cancer: Enhancing supportive care', Oncology Nursing Forum, 38, pp. 627 - 631

Kiely B; Friedlander M; Milne RL; Stanhope L; Russell P; Jenkins MA; Weideman P; McLachlan S; Grant PT, 2011, 'Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.', Familial Cancer, 10, pp. 505 - 514

Collinson I; Roberts-Thomson R; Faulkner D; Rischin D; Friedlander M; Mileshkin L, 2011, 'Carboplatin dosing in ovarian cancer: problems and pitfalls.', International Journal of Gynecological Cancer, 21, pp. 1213 - 1218

Lee CK; Gurney H; Brown C; Sorio R; Donadello N; Tulunay G; Meier W; Bacon M; Maenpaa J; Petru E; Reed N; Gebski V; Pujade-lauraine E; Lord S; Simes RJ; Friedlander M, 2011, 'Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer', British Journal of Cancer, 105, pp. 360 - 365

Bae S; Friedlander M; Scott C, 2011, 'CART-WHEEL.org can facilitate research into rare gynecological tumors.', International Journal of Gynecological Cancer, 21, pp. 1517 - 1519

Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh M; Loman N; Scott C; Friedlander M; kaufman B; Garber J; Tutt A; Robson ME, 2011, 'Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.', Journal of CLIN ONCOL, 29, pp. 4224 - 4226

Friedlander M; Trimble E; Tinker A; Alberts D; Avall-lundqvist E; Brady M; Harter P; Pignata S; Pujade-lauraine E; Sehouli J; Vergote I; Beale P; Bekkers R; Calvert P; Copeland LM; Glasspool R; Gonzalez-martin A; Katsaros D; Kim JW; Miller B; Provencher D; Rubinstein L; Atri M; Zeimet A; Bacon M; Kitchener H; Stuart GW, 2011, 'Clinical trials in recurrent ovarian cancer.', International Journal of Gynecological Cancer, 21, pp. 771 - 775

Rustin G; Vergote I; Eisenhauer E; Pujade-lauraine E; Quinn M; Thigpen T; Du bois A; Kristensen G; Jakobsen A; Sagae S; Greven K; Parmar M; Friedlander M; Cervantes A; Vermorken J, 2011, 'Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 Agreed by the gynecological cancer intergroup (GCIG)', International Journal of Gynecological Cancer, 21, pp. 419 - 423

Watts KJ; Meiser B; Conlon H; Rovelli S; Tiller K; Zorbas H; Lewis C; Neil G; Friedlander M, 2011, 'Development and evaluation of a new specialist breast care nurse role for women with metastatic breast cancer', Oncology Nursing Forum, 38, pp. 627 - 631

Peate ML; Meiser B; Hickey MS; Thewes B; Saunders C; Butow PN; Martinello R; Martinello R; Fallon-Ferguson J; Wakefield C; Zorbas H; Rovelli S; Friedlander ML, 2011, 'Development and pilot testing of a fertility decision aid for young women diagnosed with early breast cancer', The breast journal, 17, pp. 112 - 114, http://dx.doi.org/10.1111/j.1524-4741.2010.01033.x

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469

Lee CK; Friedlander M; Brown C; Gebski V; Georgoulopoulos A; Vergote I; Pignata S; Donadello N; Schmalfeldt B; Delva R; Mirza MQ; Sauthier P; Pujade-lauraine E; Lord SJ; Simes RJ, 2011, 'Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.', Journal of the National Cancer Institute, 103, pp. 1338 - 1342

Park SB; Lin CS-Y; Krishnan AV; Friedlander M; Lewis C; Kiernan MC, 2011, 'Early Progressive and Sustained Dysfunction of Sensory Axons Underlies Paclitaxel-induced Neuropathy', Muscle and Nerve, 43, pp. 367 - 374, http://dx.doi.org/10.1002/mus.21874

Webber K; Mok K; Bennett BK; Lloyd AR; Friedlander M; Juraskova I; Goldstein D, 2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344

Anglesio M; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin P; House CM; Chakravarty P; Gorringe K; Campbell I; George J, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, 17, pp. 2538 - 2548

Peate M; Meiser B; Friedlander M; Zorbas H; Rovelli S; Sansom-daly U; Sangster J; Hadzi-Pavlovic D; Hickey MS, 2011, 'It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer. An Australian Fertility Decision Aid Collaborative Group Study.', Journal of Clinical Oncology, 29, pp. 1670 - 1677

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248

Park SB; Goldstein D; Lin CS-Y; Krishnan AV; Friedlander M; Kiernan MC, 2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e

Lee CK; Simes RJ; Brown C; Lord S; Wagner U; Plante M; Vergote I; Pisano C; Parma G; Burgess AJ; Bourgeois H; Högberg T; Bentley JD; Angleitner-boubenizek L; Ferrero A; Richter B; Hirte H; Gebski V; Pfisterer J; Pujade-lauraine E; Friedlander M, 2011, 'Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.', British Journal of Cancer, 105, pp. 1144 - 1150

Harvey S; Milne RL; McLachlan S; Friedlander M; Birch KE; Weideman P, 2011, 'Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.', Breast Cancer Research and Treatment, 130, pp. 1057 - 1061

Vaughan S; Coward J; Bast R; Berchuck A; Berek JS; Brenton JD; Coukos G; Crum CC; Drapkin R; Etemadmoghadam D; Friedlander M; Gabra H; Kaye S; Lord CJ; Lengyel E; Levine DA; McNeish IA; Menon U; Mills G; Nephew KP; Oza AM; Sood A; Stronach EA; Walczak H; Bowtell D; Balkwill FR, 2011, 'Rethinking ovarian cancer: recommendations for improving outcomes.', Nature Reviews Cancer, 11, pp. 719 - 725, http://dx.doi.org/10.1038/nrc3144

Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott C, 2011, 'The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.', Asia-Pacific Journal of Clinical Oncology, 7, pp. 197 - 211

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002

Parmalee NL; Schubert C; Merriam JE; Allikmets K; Bird AC; Gillies MC; Peto T; Figueroa M; Friedlander M; Fruttiger M; Greenwood J; Moss SE; Smith LEH; Toomes C; Inglehearn CF; Allikmets R, 2010, 'Analysis of candidate genes for macular telangiectasia type 2', Molecular Vision, 16, pp. 2718 - 2726

Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J; Liedtke C, 2010, 'The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer', Breast Care, 5, pp. 364 - 365, http://dx.doi.org/10.1159/000322170

Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Clack G; Bianco AR, 2010, 'The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol', JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 30, pp. 596 - 604, http://dx.doi.org/10.3109/01443615.2010.492433

Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial', The Lancet, 376, pp. 235 - 244, http://dx.doi.org/10.1016/S0140-6736(10)60892-6

Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial', The Lancet, 376, pp. 245 - 251, http://dx.doi.org/10.1016/S0140-6736(10)60893-8

Webber K; Goldstein D; Bennett BK; Boyle FM; De Souza PL; Wilcken N; Friedlander M; Lloyd AR, 2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047

Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA, 2010, 'Erratum: Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the kathleen cuningham foundation consortium for research into familial breast cancer (kConFab) (Breast Cancer Res Treat (2010) (120) DOI: 10.1007/s10549-009-0497-8))', Breast Cancer Research and Treatment, 120, pp. 725 - 726, http://dx.doi.org/10.1007/s10549-009-0528-5

Trimble EL; Birrer MJ; Hoskins WJ; Marth C; Petryshyn R; Quinn M; Thomas GM; Kitchener HC, 2010, 'Current academic clinical trials in ovarian cancer: Gynecologic cancer intergroup and us national cancer institute clinical trials planning meeting, may 2009', International Journal of Gynecological Cancer, 20, pp. 1, http://dx.doi.org/10.1111/IGC.0b013e3181ee1c01

Gainford MC; Tinker A; Carter J; Petru E; Nicklin J; Quinn M; Hammond I; Elit L; Lenhard M; Friedlander M, 2010, 'Malignant transformation within ovarian dermoid cysts: An audit of treatment received and patient outcomes. An Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study', International Journal of Gynecological Cancer, 20, pp. 75 - 81, http://dx.doi.org/10.1111/IGC.0b013e3181c7fccf

Friedlander M, 2010, 'Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy?', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 20, http://dx.doi.org/10.1111/igc.0b013e3181f60d26

Mai PL; Friedlander M; Tucker K; Phillips KA; Hogg D; Jewett MAS; Lohynska R; Daugaard G; Richard S; Bonaïti-Pellié C; Heidenreich A; Albers P; Bodrogi I; Geczi L; Olah E; Daly PA; Guilford P; Fosså SD; Heimdal K; Liubchenko L; Tjulandin SA; Stoll H; Weber W; Easton DF; Dudakia D; Huddart R; Stratton MR; Einhorn L; Korde L; Nathanson KL; Bishop DT; Rapley EA; Greene MH, 2010, 'The international testicular cancer linkage consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred', Urologic Oncology: Seminars and Original Investigations, 28, pp. 492 - 499, http://dx.doi.org/10.1016/j.urolonc.2008.10.004

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025

Friedlander M; Hancock K; Rischin D; Messing MJ; Stringer C; Matthys GM; Ma B; Hodge J; Lager JJ, 2010, 'A phase 11, open-label study evaluating pazopanib in patients with recurrent ovarian cancer', Gynecologic Oncology, 119, pp. 32 - 37

Luckett T; King M; Butow P; Friedlander M; Paris T, 2010, 'Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change', International Journal of Gynecological Cancer, 20, pp. 664 - 684

Kiely B; Jenkins MA; McKinley J; Friedlander M; Weideman P; Milne RL; McLachlan S; Hopper JL; Phillips KA, 2010, 'Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for research into familial breast cancer', Breast Cancer Research and Treatment, 120, pp. 715 - 723

Gainford M; Tinker A; Carter J; Petru E; Nicklin J; Quinn MA; Hammond IG; Elit L; Lenhard M; Friedlander M, 2010, 'Malignant transformation within ovarian dermoid cysts:and audit of treatment received and patient outcomes', International Journal of Gynecological Cancer, 20, pp. 75 - 81

Trainer A; Meiser B; Watts KJ; Mitchell GF; Tucker K; Friedlander ML, 2010, 'Moving towards personalised medicine: Treatment- focused genetic testing of women newly diagnosed with ovarian cancer.', International Journal of Gynecological Cancer, 20, pp. 704 - 716, http://dx.doi.org/10.1111/IGC.0b013e3181dbd1a5

Friedlander M, 2010, 'Optimally debulked stage 111 ovarian cancer: intraperitoneal or intravenous chemotherapy?', International Journal of Gynecological Cancer, 20, pp. S20 - S23

Tutt A; Robson M; Garber J; Domchek SM; Friedlander M; Audeh M; Weitzel J, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-content trial', The Lancet, 24, pp. 235 - 244

Audeh M; Carmichael J; Penson R; Friedlander M, 2010, 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proff-of-concept trial.', The Lancet, 24, pp. 245 - 251

Price M; Butow PN; Bullen T; Meiser B; McKinley J; Phillips KA, 2010, 'Predictors of breast cancer screening behaviors in women with a strong family history of the disease.', Breast Cancer Research and Treatment, 124, pp. 509 - 519, http://dx.doi.org/10.1007/s10549-010-0868-1

Price MA; Zachariae R; Butow PN; deFazio A; Chauhan D; Espie CA; Friedlander M; Webb PM, 2009, 'Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor', European Journal of Cancer, 45, pp. 3262 - 3270, http://dx.doi.org/10.1016/j.ejca.2009.05.030

Mai PL; Chen BE; Tucker K; Friedlander M; Phillips KA; Hogg D; Jewett MAS; Bodrogi I; Geczi L; Olah E; Heimdal K; Fosså SD; Nathanson KL; Korde L; Easton DF; Dudakia D; Huddart R; Stratton MR; Bishop DT; Rapley EA; Greene MH, 2009, 'Younger age-at-diagnosis for familial malignant testicular germ cell tumor', Familial Cancer, 8, pp. 451 - 456, http://dx.doi.org/10.1007/s10689-009-9264-6

Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thuerlimann B; Paridaens R; Smith I; Mauriac L; Forbes JF; Price KN; Regan MM; Gelber RD; Coates AS, 2009, 'Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 361, pp. 766 - 776, http://dx.doi.org/10.1056/nejmoa0810818

Back to profile page